{
    "title": "109_hr3423",
    "content": "The \"Medical Device User Fee Stabilization Act of 2005\" is the short title of this Act. It includes amendments to the Federal Food, Drug, and Cosmetic Act. The \"Medical Device User Fee Stabilization Act of 2005\" amends Section 738 of the Federal Food, Drug, and Cosmetic Act regarding device user fees. It updates fee setting procedures and fee amounts for fiscal years. The \"Medical Device User Fee Stabilization Act of 2005\" updates fee setting procedures and amounts for fiscal years 2006 and 2007. The Secretary may use unobligated carryover balances from previous fiscal years to ensure fee revenues are available, with notice to Congress required before use. The Secretary must provide notice to Congress before using unobligated carryover balances from previous fiscal years to ensure fee revenues are available for fiscal year 2008. The definition of 'small business' is clarified as an entity with $30,000,000 or less of gross receipts or sales in its most recent Federal income tax return. In subsection (e)(2)(A) and (g)(1), the threshold for financial requirements is increased from $30,000,000 to $100,000,000. Additionally, performance goals for the Secretary in fiscal year 2005 are outlined based on appropriated funds. In fiscal year 2005, the appropriated amount, excluding fees, must be equal to or greater than $205,720,000 multiplied by the adjustment factor. If the appropriated amount is more than 1 percent less than the specified amount, certain conditions apply. In fiscal year 2005, the appropriated amount must be equal to or greater than $205,720,000 multiplied by the adjustment factor. Certain conditions apply if the appropriated amount is more than 1 percent less than the specified amount, including changes to the years specified. In subsection (h)(3), amendments are made for fiscal years 2006 and 2007, including necessary sums and changes to reporting requirements for medical device user fees. For fiscal years 2006 and 2007, the report must include information on different types of applications and fees paid by businesses with varying sales, as well as a certification on FDA expenses related to device functions. Additionally, Section 502(u) addresses misbranded devices in the Federal Food, Drug, and Cosmetic Act. Section 502(u) of the Federal Food, Drug, and Cosmetic Act addresses misbranded devices, specifically reprocessed single-use devices requiring manufacturer identification on the device or packaging label. The FDA requires reprocessed medical devices to prominently display the manufacturer's name, abbreviation, or symbol on the packaging or a detachable label for patient records. The Secretary of Health and Human Services will issue guidance on what constitutes \"prominent and conspicuous\" within 180 days of the Act's enactment. The FDA mandates that reprocessed medical devices must display the manufacturer's name, abbreviation, or symbol prominently. Section 502(u) of the Federal Food, Drug, and Cosmetic Act specifies the effective dates for these requirements. The FDA requires reprocessed medical devices to display the manufacturer's name, abbreviation, or symbol prominently. This requirement applies to devices introduced in interstate commerce after the specified effective dates in Section 502(u) of the Federal Food, Drug, and Cosmetic Act. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}